Skip to Content
Merck
CN
All Photos(2)

Documents

Safety Information

SAB4200700

Sigma-Aldrich

Anti-MR-Pro ADM antibody, Mouse monoclonal

clone MR2.1, purified from hybridoma cell culture

Sign Into View Organizational & Contract Pricing
All Photos(2)
Synonym(s):
Midregional proadrenomedullin
UNSPSC Code:
51111800
NACRES:
NA.41

biological source

mouse

Quality Level

200

conjugate

unconjugated

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

MR2.1, monoclonal

form

buffered aqueous solution

species reactivity

human

concentration

~1 mg/mL

technique(s)

immunoblotting: 1-2 μg/mL using human recombinant peptide of MR-Pro ADM (amino acid 45-92)
immunohistochemistry: 2.5-5 μg/mL using Biotin/ExtrAvidin®-Peroxidase staining system of heat-retrieved formalin-fixed, paraffin-embedded human Pancreas sections

isotype

IgG2a

UniProt accession no.

P35318

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... ADM(133)

General description

Anti-MR-Pro ADM antibody, Mouse monoclonal (MidRegional pro-Adrenomedullin) (mouse IgG2a isotype) is derived from the hybridoma MR2.1 produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with a synthetic peptide corresponding to the internal region of human Adrenomedullin (ADM), conjugated to KLH. The precursor peptide of Adrenomedullin (ADM), prepro-ADM, is processed to the circulating form of ADM. During this processing, other peptides are also being generated; PAMP (proadrenomedullin N-terminal 20 peptide) with suggested hypotensive effect, and MR-pro ADM (Mid-Regional pro-Adrenomedullin) which consists of 47 amino acid-propeptide.

Immunogen

Synthetic peptide corresponding to the internal region of human Adrenomedullin (ADM), conjugated to KLH.

Application

Anti-MR-Pro ADM antibody has been used in immunoblotting, immunohistochemistry.

Biochem/physiol Actions

MR-pro ADM (MidRegional pro-Adrenomedullin) has been suggested as a biomarker for plasma concentrations of Adrenomedullin as it is stoichiometrically generated and relatively stable in the plasma. Increased levels of MR-pro ADM were associated with an increased risk of mortality and morbidity in patients with heart failure, independent of natriuretic peptides. In dialysis patients MR-pro ADM and MR-pro ANP were shown to be associated with mortality in general and particularly with cardiovascular related mortality, with the highest risk when both parameters were elevated.

Physical form

Solution in 0.01 M phosphate buffered saline pH 7.4, containing 15 mM sodium azide

Legal Information

ExtrAvidin is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

常规特殊物品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study
Christ-Crain M, et al.
Critical Care, 9(6), R816-R816 (2005)
Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after an acute myocardial infarction
Klip I T, et al.
Heart, 97(11), 892-898 (2011)
Adrenomedullin, a multifunctional regulatory peptide.
Hinson JP, et al.
Endocrine Reviews, 21(2), 138-167 (2000)
Ghazaleh Gouya et al.
PloS one, 6(3), e17803-e17803 (2011-03-17)
High levels of the plasma peptides mid-regional pro-adrenomedullin (MR-proADM) and mid-regional pro-atrial natriuretic peptide (MR-proANP) are associated with clinical outcomes in the general population. Data in patients with chronic kidney disease are sparse. We therefore investigated the association of MR-proANP

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service